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Abstract 
Background: Chronic pulmonary disorders, such as chronic obstructive pulmonary disease 
(COPD) and fibrosing lung diseases, and atrial fibrillation (AF), are prevalent in elderly people. 
The impact of cardiac co-morbidities in the elderly, where pulmonary function is impaired, 
cannot be ignored as they influence mortality. The relationship between the prevalence of AF 
and pulmonary function is unclear. The aim of this study was to evaluate this relationship in 
participants in a health check. 
Methods: Subjects aged 40 or older (n = 2,917) who participated in a community-based 
annual health check in Takahata, Japan, from 2004 through to 2005, were enrolled in the 
study. We performed blood pressure measurements, blood sampling, electrocardiograms, 
and spirometry on these subjects.  
Results: The mean FEV1 % predicted and FVC % predicted in AF subjects was significantly 
lower than in non-AF subjects. The prevalence of AF was higher in those subjects with airflow 
limitation or lung restriction than in those without. Furthermore, AF prevalence was higher in 
those subjects with severe airflow obstruction (FEV1 %predicted < 50) than in those who had 
mild or moderate airflow obstruction (FEV1 %predicted ≥ 50), although there was no dif-
ference between the prevalence of AF in subjects with 70≤ FVC %predicted <80 lung re-
striction and those with FVC %predicted <70. Multiple logistic regression analysis revealed 
that FEV1 %predicted and FVC %predicted are independent risk factors for AF (independent 
of age, gender, left ventricular hypertrophy, and serum levels of B-type natriuretic peptide). 
Conclusion: Impaired pulmonary function is an independent risk factor for AF in the Japa-
nese general population. 
Key words: atrial fibrillation, pulmonary function, general population 
Introduction 
Long-term cigarette smoking causes respiratory 
airway injury and results in pulmonary diseases such 
as  chronic  obstructive  pulmonary  disease  (COPD) 
and lung cancer (1). COPD is characterized by airflow 
limitation  that  is  not  fully  reversible; 
post-bronchodilation  forced  expiratory  volume  in  1 
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second (FEV1)/ forced vital capacity (FVC) < 70% (2). 
In Japan, it is estimated that 10% of the general pop-
ulation have COPD (3), most  of whom are undiag-
nosed because patients with mild or moderate COPD 
show less clinical symptoms, such as dyspnea, cough, 
and  sputum.  Recently,  the  clinical  phenotype  of 
COPD was suggested to be associated with chronic 
inflammation, not only in the lung, but in the whole 
body, resulting in various co-morbidities such as un-
explained cachexia, osteoporosis, and diabetes melli-
tus (4). As we previously demonstrated, differences in 
genetic backgrounds in COPD patients are involved 
in this exaggerated inflammatory response (5-7). 
Coronary  artery  disease  is  one  of  the  most 
well-known co-morbidities seen in COPD patients (8), 
and is a risk factor that influences mortality associated 
with this disease. In addition, serum levels of B-type 
natriuretic  peptide  (BNP),  a  marker  of  congestive 
heart failure (9), are reportedly, significantly elevated 
in COPD patients (10), and COPD patients frequently 
have  cardiac  disease  (8).  Consistent  with  this,  left 
ventricular filling is reportedly impaired in patients 
with pulmonary emphysema (11). 
Atrial fibrillation (AF) is one of the most com-
mon arrhythmias. The incidence of AF is higher in the 
older  generation  (12,13),  and  its  prevalence  accord-
ingly increases with a shift to the aging population 
(14).  As  with  COPD,  the  development  of  AF  is 
thought to be involved in systemic inflammation (15), 
and known risk factors are aging (16,17), cardiac dis-
ease  (18),  hypertension  (19),  obesity  (20),  smoking 
(21,22), and hypoxia (23). A couple of cohort studies 
on the relationship between AF and COPD are avail-
able (24-26), however, their conflicting results make 
any conclusions difficult. 
Long-term  cigarette  smoking  significantly  re-
duces the vital capacity of smokers’ lungs (27), and 
cigarette smoking is a risk factor for fibrosing  lung 
diseases,  such  as  idiopathic  pulmonary  fibrosis.  In 
some fibrosing lung diseases, impairment of pulmo-
nary  vasculatures  frequently  causes  pulmonary  hy-
pertension  (28).  This  hemodynamic  alteration  may 
induce arrhythmias, such as AF. 
 We assessed the findings of electrocardiograms 
and spirometry in Japanese subjects who participated 
in  a  community-based  annual  health  check-up.  We 
evaluated  the  association  of  AF  and  impaired  pul-
monary function in this population. 
Methods 
Study population 
This study formed part of the Molecular Epide-
miological Study utilizing the Regional Characteris-
tics of 21st Century Centers of Excellence (COE) Pro-
gram and the Global COE Program in Japan. Details 
of the study methodology have been described else-
where (29). This study was approved by the institu-
tional  ethical  committee  and  all  participants  gave 
written informed consent. 
This  study utilized a community-based annual 
health  check,  in  which  all  inhabitants  of  Takahata 
town (total population 26,026) in northern Japan, who 
were aged 40 years or older, were invited to partici-
pate. This region has a resident population of 15,222 
adults,  aged  40  or  older  (7,109  males  and  8,113  fe-
males).  Since  employees  in  public  institutes  and  in 
many  companies  are  examined  annually  in  health 
check programs organized by the local health centers, 
they  usually  do  not  participate  in  the  health  check 
held  by  their  local  government,  such  as  Takahata 
town. The local government-organized health check 
covers  farmers,  employees  of  small  companies, 
self-employed persons, housewives and retirees. Four 
thousand two hundred and eighty-two adults aged 40 
years or older participated in this health check pro-
gram from June 2004 through  November 2005, and 
1,380 males and 1,735 females (a total of 3,165 sub-
jects) agreed to be enrolled in the study. Two hundred 
and  forty-eight  subjects  were  excluded  from  the 
analysis due to spirometry data that did not meet the 
Japanese Respiratory Society (JRS) criteria (30). Data 
for a total of 2,917 subjects (1,325 males, 1,592 females) 
were entered into the final statistical analyses. 
Subjects  used  a  self-reporting  questionnaire  to 
document  their  medical  histories,  smoking  habits, 
current  medications,  and  clinical  symptoms.  In  the 
questionnaire, 2.2% of subjects reported a history of 
respiratory  disease,  although  the  details  were  not 
known.  Brinkman  index  [inhaled  cigarettes  /day  × 
duration of smoking (years)] was used as an estimate 
of the amount of inhaled cigarettes in the subject’s life. 
Measurements 
Systolic  and  diastolic  blood  pressures  were 
measured with a mercury manometer, and placed on 
the right arm of seated subjects who had rested in a 
sitting position for at least 5 min before measurement. 
This was carried out twice, and the mean value was 
used  for  statistical  analysis.  Fasting  blood  samples 
were  collected  from  the  antecubital  vein  with  the 
subject in a sitting position, and samples were trans-
ferred immediately to chilled tubes. Immediately fol-
lowing serum isolation, laboratory examinations were 
performed. Of the 2,917 participants, data on serum 
BNP levels were available in 2,906 subjects. The re-
maining serum was stored at -80°C. High sensitivity 
C-reactive protein (HS CRP) levels were measured in Int. J. Med. Sci. 2011, 8 
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2010  in  the  stored  serum  samples  with  sufficient 
volume (1,206 serum samples). 
Spirometric values (FVC; FEV1; forced expiratory 
volume  in  6  seconds,  FEV6;  forced  expiratory  flow 
between  25%  and  75%  FVC,  FEF25-75;  maximum  ex-
piratory  flow  at  75%  FVC,  V75;  V50  and  V25)  were 
measured  using  standard  techniques,  with  subjects 
performing FVC maneuvers on a CHESTAC-25 part II 
EX instrument (Chest Corp., Tokyo, Japan) under the 
JRS guidelines (30). Bronchodilator was not adminis-
tered prior to measurements. The highest value from 
at  least  three  FVC  maneuvers  by  each  subject  was 
used for analysis. The results were assessed by visual 
inspection of flow-volume curves by two pulmonary 
physicians. Subjects with poor data (according to JRS 
criteria)  were  excluded  (30).  Predictive  equations 
were as described previously (27,31). Subjects whose 
FEV1/FVC was < 70% were identified as having air-
flow limitation, and those with FVC %predicted <80% 
were described as having lung restriction. According 
to GOLD criteria, the subjects with airflow limitation 
and FEV1 %predicted ≥80 were identified as having 
mild  airflow  limitation,  50≤  FEV1  %predicted  <80 
were  described  as  moderate,  and  FEV1  %predicted 
<50 were described as having severe airflow limita-
tion. In addition, subjects with lung restriction were 
divided  into  two  groups;  70≤  FVC  %predicted  <80 
and FVC %predicted <70. FVC %predicted < 70 com-
prised the bottom 2.5 percentile of all the subjects. 
A  standard  12-lead  electrocardiogram  (ECG) 
was recorded after subjects had rested sufficiently. All 
ECGs  were  read  by  cardiologists  and  classified  ac-
cording  to  the  Minnesota  Code  revised  edition  in 
1982.  Left  ventricular  hypertrophy  (LVH)  was  con-
sidered present if, 1) the summation of R amplitude in 
lead V5 or V6, and S amplitude in lead V1, was 4.0 mV 
or over, and 2) R amplitude in lead V5 or V6 was 2.6 
mV or over (32). 
Chest X-ray findings and the final diagnosis of 
each subject were unavailable in the database of this 
study. 
Statistical analysis 
The  Mann-Whitney  U  test  for  non-parametric 
data  was  used  to  analyze  differences  between  two 
groups. Fisher’s exact test was used to evaluate dif-
ferences in proportions. These comparisons and the 
logistic  regression  analyses  were  performed  using 
JMP version 8 software (SAS Institute Inc., Cary, NC, 
USA). Data in the figures are shown as mean ± SD. 
Significance was inferred for differences with P < 0.05. 
Results 
Characteristics of the subjects are summarized in 
Table 1.  
 
Table 1. The characteristics of study subjects with and without atrial fibrillation (AF), as determined by electrocardiogram 
 
*: Brinkman index is inhaled cigarettes /day × duration of smoking (years). 
Age, BMI, BPs, Brinkman index, HbA1c, FEV1 %predicted and FVC %predicted are expressed as mean ± S.D. BNP is expressed as a median 
(interquartile range). 
AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; LVH, left ventricular hypertrophy; HbA1c, hemoglobin A1c; BNP, B-type 
natriuretic peptide; FEV1 %predicted, percent predicted forced expiratory volume in 1 second; FVC %predicted, percent predicted forced 
vital capacity Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
517 
Table 2. Distribution of atrial fibrillation (AF) relative to age group (generation), gender, serum B-type natriuretic peptide 
(BNP) level, co-morbidity of left ventricular hypertrophy (LVH), degree of airflow limitation (AFL), and lung restriction (LR). 
 
Median (interquartile range) value of BNP was 18.75 (10.2 – 34.3) pg/mL. 
* P < 0.05 vs. “no LVH” and “no AFL”, ** P < 0.001 vs. “age 40-49”, “male”, “1st BNP quartile”, “no AFL” and “no LR”, # P < 0.05 vs. “AFL 
(%FEV1 ≥ 50)”, ## P < 0.001 vs. “age 50-59” and “2nd BNP quartile”, ¶¶ P < 0.001 vs. “age 60-69” and “3rd BNP quartile” in Fisher’s exact test 
%FEV1, percent predicted forced expiratory volume in 1 second; %FVC, percent predicted forced vital capacity 
 
 
The prevalence of AF was 1.5%. Subjects with AF 
were significantly older than subjects without AF, and 
AF was also more prevalent in males than females. 
Body mass index (BMI), blood pressure (BP), Brink-
man  index,  and  hemoglobin  A1c  (HbA1c),  did  not 
significantly differ between subjects with and without 
AF. Left ventricular hypertrophy was more prevalent 
in the AF group, and serum levels of B-type natriu-
retic peptide (BNP) were significantly higher in sub-
jects with AF than those without. Interestingly, FEV1 
%predicted  and  FVC  %predicted  were  significantly 
lower in those subjects with AF than those without. 
As  previously  demonstrated,  the  prevalence  of  air-
flow limitation in the Takahata study was 10.6% (27). 
The prevalence of lung restriction in this study pop-
ulation was 9.89% in males, and 6.28% in females. The 
relative  risk  of  habitual  cigarette  smoking  for  the 
prevalence of lung restriction was 1.876 (95% confi-
dence interval: 1.284 – 2.740) in males, and 1.334 (95% 
confidence interval: 0.731 – 2.433) in females. 
As shown in Table 2, the prevalence of AF was 
significantly higher in the older subjects (Table 2A), 
males (Table 2B), subjects in the highest BNP-quartile 
group (Table 2C), and those with LVH (Table 2D). In 
addition, AF was more prevalent in subjects with air-
flow limitation, compared to those without (Table 2E). 
Furthermore, subjects with severe airflow limitation 
(FEV1 %predicted < 50) had a higher prevalence of AF 
than subjects with no airflow limitation and subjects 
with mild/moderate airflow limitation (FEV1 %pre-
dicted ≥ 50), although AF prevalence in the subjects 
with mild/moderate airflow limitation did not differ Int. J. Med. Sci. 2011, 8 
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from those without airflow limitation. In addition, AF 
was more prevalent in subjects with lung restriction, 
compared to those without (Table 2F). Both subjects 
with  70≤  FVC  %predicted  <80  lung  restriction  and 
those  with  FVC  %predicted  <70  restriction  had  a 
higher prevalence of AF than subjects without lung 
restriction. However, the difference in AF prevalence 
was not statistically significant between subjects with 
70≤ FVC %predicted <80 lung restriction and those 
with FVC %predicted <70 restriction (Table 2F). 
As  shown  in  Table  3A,  FEV1  %predicted  was 
significantly associated with age and serum BNP lev-
els while FVC %predicted was significantly associated 
with BNP levels, but not age. Also, these pulmonary 
function  parameters  were  significantly  decreased  in 
males and subjects with LVH (Table 3B). Thus, age, 
gender, co-morbidity of LVH, and BNP levels might 
be confounders for the relationship between AF and 
pulmonary dysfunction.  
To  investigate  whether  the  degree  of  airflow 
limitation  (FEV1  %predicted)  and  lung  restriction 
(FVC %predicted) are independent risk factors for AF 
from these significant factors, we performed univari-
ate and multivariate logistic regression analyses. Be-
cause  FEV1  %predicted  and  FVC  %predicted  had  a 
very  strong  correlation  (Pearson  product-moment 
correlation coefficient; r =0.85, P <0.00001), these two 
factors were separately assessed. As shown in Table 4, 
all  variables  were  independent  risk  factors  for  the 
presence of AF. Importantly, airflow limitation (FEV1 
%predicted)  and  lung  restriction  (FVC  %predicted) 
were shown to be significant risk factors for AF by 
multivariate logistic regression analysis. 
Table 5 summarizes pulmonary function of the 
subjects  relative  to  presence  of  AF.  All  spirometric 
values  (FEV6  %predicted,  FEV1/FVC,  FEV1/FEV6, 
FEF25-75 %predicted, V75 %predicted, V50 %predicted 
and V25 %predicted) were significantly lower in sub-
jects with AF than in those without. 
To  investigate  the  involvement  of  systemic  in-
flammation in the mechanisms of AF development in 
the  subjects  with  reduced  pulmonary  function,  HS 
CRP levels were measured in  some subjects, as de-
scribed in Methods. As shown in Table 6A, HS CRP 
levels  were  significantly  elevated  in  those  subjects 
with airflow limitation, compared  to those without. 
Although not statistically significant, HS CRP levels 
tended to be higher in subjects with lung restriction 
and with AF, compared  to those without (Table 6B 
and 6C). 
 
Table 3. Association of pulmonary function with age and serum B-type natriuretic peptide (BNP) levels, and pulmonary 
function relative to gender and co-morbidity of left ventricular hypertrophy (LVH) findings by electrocardiogram. 
 
FEV1 %predicted and FVC %predicted are expressed as mean ± S.D. 
* P < 0.05 vs. “no LVH”, ** P < 0.001 vs. “male” 
Because the distribution of BNP was highly skewed toward the larger values, the logarithm-transformed BNP was used in this analysis. 
FEV1 %predicted, percent predicted forced expiratory volume in 1 second; FVC %predicted, percent predicted forced vital capacity 
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Table 4. Univariate and multivariate logistic regression analysis for the presence of atrial fibrillation in this study 
 
LVH, left ventricular hypertrophy; BNP, B-type natriuretic peptide; FEV1 %predicted, Percent predicted forced expiratory volume in 1 se-
cond; FVC %predicted, percent predicted forced vital capacity; OR, odds ratio; 95%CI, 95% confidence interval  
 
 
Table 5. Comparison of spirometric measurements on subjects with and without atrial fibrillation (AF), as determined by 
electrocardiogram. 
 
Data are expressed as mean ± S.D. 
FEVx, forced expiratory volume in X second; FEF25-75, forced expiratory flow between 25% and 75% FVC; Vx, maximum expiratory flow at 
X% FVC 
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Table 6. Comparison of high sensitivity C-reactive protein (HS CRP) values in subjects with and without airflow limitation 
(AFL), lung restriction (LR) or atrial fibrillation (AF) 
 
HS CRP levels were measured in 1,206 stored serum samples. 
The subjects whose FEV1/FVC was less than 0.7, or whose FVC %predicted was less than 0.8 were identified as having AFL, or LR, respec-
tively. 
Data are expressed as median (interquartile range). 
 
 
Discussion 
In this study, mean FEV1 %predicted and FVC 
%predicted  in  AF  subjects  were  significantly  lower 
than in non-AF subjects. AF prevalence was higher in 
those  subjects  with  airflow  limitation  or  lung  re-
striction than those without. Furthermore, the preva-
lence of AF was higher in those subjects who had se-
vere  airflow  obstruction  (FEV1  %predicted  <  50) 
compared  to  those  with  mild  or  moderate  airflow 
obstruction (FEV1 %predicted ≥ 50). Multiple logistic 
regression  analysis  revealed  that  both  FEV1  %pre-
dicted, representing the degree of airflow limitation in 
COPD  patients,  and  FVC  %predicted,  representing 
the lung size of the subjects, were independent (from 
age, male gender, the co-morbidity of LVH, and BNP 
levels) risk factors for AF. 
To date, there are a few epidemiological studies 
on the relationship between the incidence of AF and 
pulmonary function (24-26). In the Framingham Heart 
Study, 4,731 subjects were followed for 38 years, and 
they concluded that the incidence of AF did not cor-
relate  with  FEV1  %predicted  (24).  In  the  Ren-
frew/Paisley Study, 15,406 subjects were followed for 
4 years and, although they showed that FEV1 %pre-
dicted was not an independent risk factor for the in-
cidence of AF, the subjects with AF had lower FEV1 
%predicted  than  those  subjects  without  (26).  In  the 
Copenhagen City Heart Study, 13,430 subjects were 
followed for 5 years, and they demonstrated that the 
odds ratio for the incidence of AF in subjects whose 
FEV1 %predicted was 60% to 80% was significantly 
higher than subjects whose FEV1 %predicted was 80% 
and  over  (25).  However,  in  those  subjects  whose 
FEV1% predicted was below 60% the incidence of AF 
was not significantly higher than the reference group 
(25). They demonstrated that the relative risk of hos-
pital  admission  for  AF  was  significantly  associated 
with the degree of FEV1 %predicted (25). Taken to-
gether, it was suggested that there was a relationship 
between AF and the impairment of pulmonary func-
tion,  but  this  relationship  was  not  conclusive.  Alt-
hough  our  study  was  a  cross-sectional  one,  we 
showed the significant association of the prevalence of 
AF  with  impairment  of  pulmonary  function.  Most 
importantly  we  demonstrated  that  the  parameters 
indicating the degree of airflow limitation and lung 
restriction,  FEV1  %predicted  and  FVC  %predicted, 
were risk factors for the prevalence of AF and were 
independent  of  various  other  AF  risk  factors,  espe-
cially cardiac dysfunction, as indicated by BNP levels. 
In contrast with the Copenhagen  City  Heart Study, 
there were many more subjects with AF in those sub-
jects  with  severe  airflow  limitation.  This  was  even 
more impressive given that the prevalence of AF in 
the severe airflow limitation group was even higher 
than the prevalence of AF in the group with abnormal 
cardiac findings, such as LVH (14.28% vs. 4.39%). 
Coronary  artery  disease  is  a  frequent 
co-morbidity  in  patients  with  COPD.  Many  of  our 
subjects  with  airflow  limitation  were  suggested  to 
have COPD, as this disease is one of the major causes Int. J. Med. Sci. 2011, 8 
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of airflow limitation in Japan. However, since the re-
lationship between AF and reduced pulmonary func-
tion was independent of serum BNP levels, which is a 
well-known  marker  of  cardiac  damage,  it  was  not 
likely that cardiac damage induced by chronic respir-
atory  disease  was  a  primary  factor  in  AF  develop-
ment.  The  mechanisms  involved  in  the  relationship 
between  AF  and  reduced  pulmonary  function  are 
suggested to be: 1) hypoxia, 2) elevation of pulmonary 
pressure, and 3) chronic inflammation.  
First,  subjects  with  severely-impaired  pulmo-
nary function may have hypoxia. Hypoxia reportedly 
induces sympathetic drive, resulting in the incidence 
of  AF  (33).  This  may  be  one  of  the  mechanisms 
whereby AF is induced in subjects with airflow limi-
tation.  Unfortunately,  PaO2,  measured  by  arterial 
blood gas analysis, and oxygen saturation, measured 
by pulse oximetry, were not assessed in this health 
check program, as it was not hospital-based clinical 
research. However, as shown in Table 2E and 2F, the 
finding that the prevalence of AF was much higher in 
the  group  with  severely  impaired  pulmonary  func-
tion, supports this hypothesis. 
Second, subjects with reduced pulmonary func-
tion may have elevated pulmonary artery pressure. In 
patients  with  COPD,  pulmonary  hypertension  is 
sometimes induced by a loss of pulmonary vascula-
ture  and  hypoxic  vascular  contraction.  In  some  fi-
brosing  lung  diseases,  impairment  of  pulmonary 
vasculatures frequently causes pulmonary hyperten-
sion (28). Ectopic beats that initiate AF are reported to 
often originate in the pulmonary vein (34). Kang et al. 
demonstrated  the  elevation  of  pulmonary  artery 
pressure and reduced pulmonary function in AF pa-
tients (35). This alteration of hemodynamics may in-
duce arrhythmias, such as AF. 
Third, chronic systemic inflammation is reported 
to be involved in the pathogenesis of some chronic 
respiratory  disease,  such  as  COPD  and  bronchial 
asthma  (4,36).  Circulating  pro-inflammatory  cyto-
kines, such as interleukin-6 and tumor necrosis fac-
tor-alpha, are elevated in such patients (36). Recently, 
the involvement of  systemic  inflammation was also 
suggested in the pathogenesis of AF  (15). Anatomi-
cally,  the  pulmonary  circulation  flows  directly  into 
the left atrium through the pulmonary vein where the 
trigger for AF is initiated. Thus, chronic inflammation 
originating  from  the  lung  may  trigger  AF.  In  this 
study, we measured HS CRP (an indicator of systemic 
inflammation) in some of the subjects. We showed no 
significant  difference  in  HS  CRP  levels  in  AF  and 
non-AF subjects. However, only 1,206 serum samples 
out of a total of 2,917 subjects were available for this 
assay. Furthermore, there were only 19 samples from 
subjects with AF. Therefore, a larger sample number 
may be required to prove the involvement of chronic 
systemic inflammation in  the mechanism of AF de-
velopment in subjects with reduced pulmonary func-
tion. 
The  details  of  airflow  limitation  and  lung  re-
striction in this study population were not specified 
because, 1) the self-reporting question on the history 
of respiratory disease only required a yes/no answer, 
2) there was no information on chest X-ray findings 
or, 3) the final diagnosis. COPD and bronchial asthma 
are the most likely cause of airflow limitation in this 
study population (3,37). The prevalence of fibrosing 
lung diseases is not as high as COPD and bronchial 
asthma. Even the prevalence of idiopathic pulmonary 
fibrosis, one of the most common fibrosing lung dis-
eases, is estimated to be only 3.44 per 100,000 people 
in Japan (38). As we previously demonstrated, FVC 
%predicted  in  the  general  Japanese  population  was 
inversely associated with the pack-years of cigarette 
smoking (27). Thus, although the precise etiology of 
lung  restriction  is  unclear,  the  habit  of  cigarette 
smoking may play an important role in reduced FVC 
values. 
Another  possible  limitation  in  this  study  was 
sampling bias. Twenty-eight percent of adults aged 40 
years or older came to receive this health examination, 
organized by Takahata town, and 74% of these were 
enrolled in this study. Workers in the public institutes 
and many companies did not participate in this re-
search due to reasons described in the  Methods. We 
cannot deny the possibility that the difference in jobs 
or  life-styles  between  participants  and 
non-participants  may  affect  the  results  of  this  re-
search. 
In  conclusion,  we  demonstrated  that  impaired 
pulmonary function is an independent risk factor for 
AF in the general Japanese population. There were, 
however,  some  study  limitations,  such  as  sampling 
bias and lack of data  for  blood  oxygen, pulmonary 
artery pressure, and details of respiratory diseases in 
the subjects. Physicians  should pay attention to the 
status  of  pulmonary  function  in  patients  with  AF. 
Early intervention for hidden chronic lung disorders, 
such as COPD, may improve the prognosis of AF pa-
tients. 
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